<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-0-00255</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Principle of the test method.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1) Laboratory rodents are exposed to one of several  <!-- PJG 0012 frnewline --> concentration levels of a test atmosphere for at least six hours  <!-- PJG 0012 frnewline --> daily over a period of 90 days. At the end of the exposure  <!-- PJG 0012 frnewline --> period, the animals are anaesthetized, perfused  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in situ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  with  <!-- PJG 0012 frnewline --> fixative, and tissues in the nervous system are examined grossly  <!-- PJG 0012 frnewline --> and prepared for microscopic examination. Starting with the  <!-- PJG 0012 frnewline --> highest dosage level, tissues are examined under the light  <!-- PJG 0012 frnewline --> microscope for morphologic changes, until a no-observed-adverse- <!-- PJG 0012 frnewline --> effect level is determined. In cases where light microscopy has  <!-- PJG 0012 frnewline --> revealed neuropathology, the NOAEL may be confirmed by electron  <!-- PJG 0012 frnewline --> microscopy.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (2) The tests described herein may be combined with any  <!-- PJG 0012 frnewline --> other toxicity study, as long as none of the requirements of  <!-- PJG 0012 frnewline --> either are violated by the combination. Specifically, this assay  <!-- PJG 0012 frnewline --> may be combined with a subchronic toxicity study, pursuant to  <!-- PJG 0012 frnewline --> provisions in &sect;79.62.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Limit test.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> If a test at one dose level of the highest  <!-- PJG 0012 frnewline --> concentration that can be achieved while maintaining a particle  <!-- PJG 0012 frnewline --> size distribution with a mass median aerodynamic diameter (MMAD)  <!-- PJG 0012 frnewline --> of 4 micrometers (&mu;m) or less, using the procedures described in  <!-- PJG 0012 frnewline --> paragraph (a) of this section, produces no observable toxic  <!-- PJG 0012 frnewline --> effects and if toxicity would not be expected based upon data of  <!-- PJG 0012 frnewline --> structurally related compounds, then a full study using three  <!-- PJG 0012 frnewline --> dose levels might not be necessary. Expected human exposure  <!-- PJG 0012 frnewline --> though may indicate the need for a higher dose level.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (e)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Test procedures <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Animal selection_ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Species and strain.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Testing shall be performed in the  <!-- PJG 0012 frnewline --> species being used in other NTX tests. A standard strain of  <!-- PJG 0012 frnewline --> laboratory rat is recommended. The choice of species shall take  <!-- PJG 0012 frnewline --> into consideration such factors as the comparative metabolism of  <!-- PJG 0012 frnewline --> the chemical and species sensitivity to the toxic effects of the  <!-- PJG 0012 frnewline --> test substance, as evidenced by the results of other studies, the  <!-- PJG 0012 frnewline --> potential for combined studies, and the availability of other  <!-- PJG 0012 frnewline --> toxicity data for the species.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Age.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animals shall be at least ten weeks of age at  <!-- PJG 0012 frnewline --> the start of exposure.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sex.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Both sexes shall be used unless it is  <!-- PJG 0012 frnewline --> demonstrated that one sex is refractory to the effects of  <!-- PJG 0012 frnewline --> exposure.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Number of Animals.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A minimum of ten animals per group  <!-- PJG 0012 frnewline --> shall be used. The tissues from each animal shall be examined  <!-- PJG 0012 frnewline --> separately.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Control Groups. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (i) A concurrent control group, exposed to clean, filtered  <!-- PJG 0012 frnewline --> air only, is required.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (ii) The laboratory performing the testing shall provide  <!-- PJG 0012 frnewline --> positive control data, e.g., results from repeated acrylamide  <!-- PJG 0012 frnewline --> exposure, as evidence of the ability of their histology  <!-- PJG 0012 frnewline --> procedures to detect neurotoxic endpoints. Positive control data  <!-- PJG 0012 frnewline --> shall be collected at the time of the test study unless the  <!-- PJG 0012 frnewline --> laboratory can demonstrate the adequacy of historical data for  <!-- PJG 0012 frnewline --> the planned study.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (iii) A satellite group of 10 female and 10 male test  <!-- PJG 0012 frnewline --> subjects shall be treated with the highest concentration level  <!-- PJG 0012 frnewline --> for the duration of the exposure and observed thereafter for  <!-- PJG 0012 frnewline --> reversibility, persistence, or delayed occurrence of toxic  <!-- PJG 0012 frnewline --> effects during a post-treatment period of not less than 28 days.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Inhalation exposure. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (i) All data developed within this study shall be in accordance with good laboratory practice provisions under &sect; <!-- PJG 0012 frnewline --> 79.60.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (ii) The general conduct of this study shall be in  <!-- PJG 0012 frnewline --> accordance with the vehicle emissions inhalation exposure  <!-- PJG 0012 frnewline --> guideline in &sect;79.61.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (5)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Study conduct <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Observation of animals.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> All toxicological (e.g.,  <!-- PJG 0012 frnewline --> weight loss) and neurological signs (e.g., motor disturbance)  <!-- PJG 0012 frnewline --> shall be recorded frequently enough to observe any abnormality,  <!-- PJG 0012 frnewline --> and not less than weekly.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (ii) The following is a minimal list of measures that shall  <!-- PJG 0012 frnewline --> be noted:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (A) Body weight;  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (B) Subject's reactivity to general stimuli such as removal  <!-- PJG 0012 frnewline --> from the cage or handling;  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (C) Description, incidence, and severity of any  <!-- PJG 0012 frnewline --> convulsions, tremors, or abnormal motor movements in the home  <!-- PJG 0012 frnewline --> cage;  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (D) Descriptions and incidence of posture and gait  <!-- PJG 0012 frnewline --> abnormalities observed in the home cage; and  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (E) Description and incidence of any unusual or abnormal  <!-- PJG 0012 frnewline --> behaviors, excessive or repetitive actions (stereotypies),  <!-- PJG 0012 frnewline --> emaciation, dehydration, hypotonia or hypertonia, altered fur  <!-- PJG 0012 frnewline --> appearance, red or crusty deposits around the eyes, nose, or  <!-- PJG 0012 frnewline --> mouth, and any other observations that may facilitate  <!-- PJG 0012 frnewline --> interpretation of the data.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sacrifice of animals <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The goal of the techniques outlined for  <!-- PJG 0012 frnewline --> sacrifice of animals and preparation of tissues is preservation  <!-- PJG 0012 frnewline --> of tissue morphology to simulate the living state of the cell.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Perfusion technique.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animals shall be perfused  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in situ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG 0012 frnewline --> by a generally recognized technique. For fixation suitable for  <!-- PJG 0012 frnewline --> light or electronic microscopy, saline solution followed by  <!-- PJG 0012 frnewline --> buffered 2.5 percent glutaraldehyde or buffered 4.0 percent  <!-- PJG 0012 frnewline --> paraformaldehyde, is recommended. While some minor modifications  <!-- PJG 0012 frnewline --> or variations in procedures are used in different laboratories, a  <!-- PJG 0012 frnewline --> detailed and standard procedure for vascular perfusion may be  <!-- PJG 0012 frnewline --> found in the text by Zeman and Innes (1963), Hayat (1970), and  <!-- PJG 0012 frnewline --> Spencer and Schaumburg (1980) under paragraph (g) of this  <!-- PJG 0012 frnewline --> section. A more sophisticated technique is described by Palay and  <!-- PJG 0012 frnewline --> Chan-Palay (1974) under paragraph (g) of this section.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Removal of brain and cord.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> After perfusion, the bony  <!-- PJG 0012 frnewline --> structure (cranium and vertebral column) shall be exposed.  <!-- PJG 0012 frnewline --> Animals shall then be stored in fixative-filled bags at 4  <!-- PJG 0040 degreeslatlong --> &cir;C for  <!-- PJG 0012 frnewline --> 8&hyph;12 hours. The cranium and vertebral column shall be removed  <!-- PJG 0012 frnewline --> carefully by trained technicians without physical damage of the  <!-- PJG 0012 frnewline --> brain and cord. Detailed dissection procedures may be found in  <!-- PJG 0012 frnewline --> the text by Palay and Chan-Palay (1974) under paragraph (g) of  <!-- PJG 0012 frnewline --> this section. After removal, simple measurement of the size  <!-- PJG 0012 frnewline --> (length and width) and weight of the whole brain (cerebrum,  <!-- PJG 0012 frnewline --> cerebellum, pons-medulla) shall be made. Any abnormal coloration  <!-- PJG 0012 frnewline --> or discoloration of the brain and cord shall also be noted and  <!-- PJG 0012 frnewline --> recorded.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            